In this podcast we’ll be covering some of the latest updates in immunotherapy for head and neck cancer. Ezra Cohen, MD, FRCPSC, FASCO, Moores Cancer Center at UC San Diego Health, San Diego, CA, discusses the clinical activity of petosemtamab, a bispecific antibody targeting EGFR and LGR5, in patients with head and neck squamous carcinoma (HNSCC). Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, presents findings from a Phase II trial (NCT03468218) of pembrolizumab and cabozantinib in patients HNSCC. Ari Rosenberg, MD, Yale School of Medicine, New Haven, CT, describes the trial design of the Phase II DEPEND trial (NCT03944915), which assessed neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation (CRT) in locoregionally advanced HPV-negative HNSCC. Blessie Elizabeth Nelson, MBBS, DMRT, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing study investigating the synergy between the potential efficacy of Clostridium novyi with pembrolizumab. Lastly, Heath Devin Skinner, MD, PhD, Hillman Cancer Center, Pittsburgh, PA, shares findings from the Phase II study (NCT03715946), which aimed to investigate treatment de-intensification for resected human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) by adding nivolumab to a reduced radiation therapy (RT) regimen.